Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Pfizer
Age
13–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Concurrent Medication:
Allowed:
Immunosuppressant therapy.
Antiviral therapy such as zidovudine.
Prophylaxis for Pneumocystis carinii pneumonia.
Aerosolized pentamidine.
Concurrent Treatment:
Allowed:
Radiation therapy for mucocutaneous Kaposi's sarcoma.
You may not be if
Patients must have a baseline cerebrospinal fluid (CSF) culture-positive for Cryptococcus neoformans.
Written informed consent must be obtained for each patient, either from the patient himself or from the patient's legal guardian.
Each individual patient must be approved by Pfizer Central Research prior to study entry.
Prior Medication:
Allowed:
Immunosuppressant therapy.
Antiviral therapy such as zidovudine.
Prophylaxis for Pneumocystis carinii pneumonia.
Aerosolized pentamidine.
Co-existing Condition:
Patients with the following are excluded:
Evidence of acute or chronic meningitis based upon any etiology other than cryptococcosis.
History of allergy to or intolerance of imidazoles or azoles.
Moderate or severe liver disease.
Concurrent Treatment:
Excluded:
Lymphocyte replacement.
Patients with the following are excluded:
Evidence of acute or chronic meningitis based upon any etiology other than cryptococcosis.
History of allergy to or intolerance of imidazoles or azoles.
Moderate or severe liver disease.
Satisfactory response to amphotericin B and have received a total amphotericin B dose of 15 mg/kg or more since CSF culture documentation of the current episode of acute cryptococcal meningitis.
Life expectancy of \< 2 weeks.
Prior Medication:
Excluded:
Coumadin-type anticoagulants.
Oral hypoglycemics.
Barbiturates.
Phenytoin.
Immunostimulants.
Investigational drugs or approved (licensed) drugs for investigational indications.
